Surrozen, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 24, 2025, details a material definitive agreement entered into by Surrozen, Inc. (SRZN) involving a two-tranche private placement of equity securities. The report also covers the appointment of a new director and related party transactions.
Key Financial Metrics and Capital Raise
- First Tranche Proceeds: The Company raised approximately $76.4 million in gross proceeds from the sale of 6,586,415 Units (comprising Common Stock, Pre-Funded Warrants, and Series E Common Warrants).
- Purchase Price: Units were sold at $11.60 per Share Unit and $11.5999 per Pre-Funded Warrant Unit.
- Second Tranche Commitment: Purchasers committed to an additional $98.6 million in gross proceeds for 8,499,821 Units, contingent on specific milestones.
- Warrant Terms: Series E Common Warrants have an exercise price of $11.54 per share and expire five years from issuance. Pre-Funded Warrants have an exercise price of $0.0001.
- Related Party Income: The Company recognized $0.4 million in sublease income from Nura Bio, Inc. during the year ended December 31, 2024.
Material Changes and Agreements
- Conditional Second Closing: The second tranche of the private placement is contingent upon the FDA granting clearance for the Company's Investigational New Drug Application (IND) for SZN-8141 on or before October 31, 2026. The closing cannot occur prior to six months and one day following the First Closing.
- Warrant Amendments: In connection with the financing, all outstanding Series C and Series D warrants were cancelled. The exercise prices for Series A and Series B warrants were reduced to $11.54 (or $12.45 for management-held warrants).
- Registration Rights: The Company agreed to file a registration statement for the resale of the new securities within 30 days of each closing.
Management Commentary, Risks, and Governance
- Director Appointment: Tim Kutzkey, Ph.D., was appointed as a Class I Director. He receives a $35,000 annual retainer and an initial stock option grant for 2,666 shares.
- Related Party Transactions:
- TCGFB Collaboration: A strategic research agreement with TCGFB, Inc. (affiliated with Dr. Kutzkey's firm, The Column Group) involves up to $6.0 million in fees and a warrant for 3.4 million shares of TCGFB stock.
- Nura Bio Sublease: The Company subleases space to Nura Bio, Inc., where Dr. Kutzkey serves as Chairman.
- Investor Participation: Entities affiliated with The Column Group participated in both tranches of the private placement.
- Risks: The realization of the second tranche funding ($98.6 million) is not guaranteed and depends on regulatory clearance for SZN-8141. Failure to achieve the milestone or terminate the program affects the obligation to purchase units and the validity of Series E warrants.
Investor Verification Checklist
- Verify the status of the SZN-8141 IND application with the FDA to assess the likelihood of the $98.6 million second tranche closing.
- Review the dilution impact of the 6,586,415 Units issued in the first tranche and the potential 8,499,821 Units in the second tranche.
- Confirm the terms of the cancelled Series C and D warrants and the reduced exercise prices for Series A and B warrants to understand the total potential share count.
- Examine the related party agreements with TCGFB and Nura Bio for potential conflicts of interest or financial dependencies.
- Monitor the filing of the registration statement required under the Registration Rights Agreement to ensure liquidity for the new securities.